Home > Insider Trading > Filing (0001127602-22-018097)

Filing Details

Accession Number:: 0001127602-22-018097
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-06-24 12:33:19
Reporting Period:: 2022-06-22

Accepted Time:: 2022-06-24 12:33:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
794172	Meridian Bioscience Inc	VIVO	In Vitro & In Vivo Diagnostic Substances (2835)	310888197

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1719325	P. John Kenny	3471 River Hills Drive Cincinnati OH 45244	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-06-22	44,651	$14.50	309,782	No	4	M	Direct
Common Stock	Disposition	2022-06-22	44,651	$29.72	265,131	No	4	S	Direct
Common Stock	Acquisiton	2022-06-23	5,349	$14.50	270,480	No	4	M	Direct
Common Stock	Acquisiton	2022-06-23	14,607	$10.10	285,087	No	4	M	Direct
Common Stock	Disposition	2022-06-23	19,956	$29.98	265,131	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2022-06-22	44,651	$0.00	44,651	$14.50
Common Stock	Stock Options (Right to Buy)	Disposition	2022-06-23	5,349	$0.00	5,349	$14.50
Common Stock	Stock Options (Right to Buy)	Disposition	2022-06-23	14,607	$0.00	14,607	$10.10

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,349	2027-10-09	No	4	M	Direct
0	2027-10-09	No	4	M	Direct
141,035	2029-11-05	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.50 to $29.94. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.61 to $30.13. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
These non-qualified options were awarded under the 2012 Stock Incentive Plan upon Mr. Kenny being hired as Chief Executive Officer. The options vested in four (4) equal installments from the date of grant until fully vested on October 9, 2021.
The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date.